These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 19152958)

  • 1. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
    Mease PJ; Russell IJ; Kajdasz DK; Wiltse CG; Detke MJ; Wohlreich MM; Walker DJ; Chappell AS
    Semin Arthritis Rheum; 2010 Jun; 39(6):454-64. PubMed ID: 19152958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.
    Chappell AS; Littlejohn G; Kajdasz DK; Scheinberg M; D'Souza DN; Moldofsky H
    Clin J Pain; 2009 Jun; 25(5):365-75. PubMed ID: 19454869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
    Arnold LM; Zhang S; Pangallo BA
    Clin J Pain; 2012; 28(9):775-81. PubMed ID: 22971669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain response profile of patients with fibromyalgia treated with duloxetine.
    Bradley LA; Wohlreich MM; Wang F; Gaynor PJ; Robinson MJ; D'Souza DN; Mease PJ
    Clin J Pain; 2010; 26(6):498-504. PubMed ID: 20551724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.
    Skljarevski V; Zhang S; Chappell AS; Walker DJ; Murray I; Backonja M
    Pain Med; 2010 May; 11(5):648-57. PubMed ID: 20546509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Distler O; Eich W; Dokoupilova E; Dvorak Z; Fleck M; Gaubitz M; Hechler M; Jansen JP; Krause A; Bendszus M; Pache L; Reiter R; Müller-Ladner U
    Arthritis Rheum; 2010 Jan; 62(1):291-300. PubMed ID: 20039417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
    Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
    Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.